Abstract:In our previous study, it was demonstrated that the Stathmin1 (STMN1) is overexpressed in gastric cancer (GC) and that its high expression level is associated with tumor invasion and metastasis. Epithelial-mesenchymal transition (EMT) has also been shown to be critically involved in GC invasion and metastasis. Certain studies have indicated that STMN1 may serve an important role in the EMT process. However, the association between STMN1 expression and EMT-associated markers, as well as clinicopathological characteristics of patients with GC, remains unclear. The aim of the present study was to investigate the clinicopathological significance and prognostic value of STMN1 and EMT-associated markers in GC. The expression of STMN1 and the EMT-associated proteins E-cadherin (E-Cad) and vimentin (VIM) were analyzed by immunohistochemistry in GC and adjacent non-tumorous tissues. Associations between the expression of these markers and clinicopathological parameters were analyzed. The association between STMN1 expression and EMT-associated markers was investigated in the GC cell lines BGC-803 and SGC-7901. The results revealed that STMN1 was expressed in 63.5% of the 167 GC tissues, which was significantly higher than the percentage observed in the adjacent non-tumorous tissues (P=0.003). The STMN1 expression was demonstrated to be positively associated with the VIM levels (P=0.001) and negatively associated with the E-Cad levels (P=0.022) in GC tissues. The STMN1 expression was associated with Lauren's Classification, invasion depth, lymph node metastasis and pathological Tumor-Node-Metastasis (pTNM) stage (P<0.05). In the univariate analyses, the high E-Cad expression was a positive prognostic indicator for overall survival, whereas the high STMN1 and VIM expression was a negative indicator. COX multiple regression analysis demonstrated that the pTNM stage [hazard ratio (HR) 1.912, 95% confidence interval (CI): 1.282-2.851, P=0.001] and E-Cad expression (HR 0.403, 95% CI: 0.249-0.650, P=0.000) were independent prognostic factors. It was also revealed that the expression level of E-Cad decreased, while the expression level of VIM increased by depleting STMN1 levels in GC cells. The present results suggest that the aberrant expression of STMN1 may promote tumor progression through EMT in GC.

STMN1 As a Candidate Gene Associated with Atypical Meningioma Progression.

Factors Related to the Post-operative Recurrence of Atypical Meningiomas

Association Of Stmn1 With Survival In Solid Tumors: A Systematic Review And Meta-Analysis

Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients

High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma

Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer.

Clinical Significance of Stathmin1 Expression and Epithelial-Mesenchymal Transition in Curatively Resected Gastric Cancer.

Stanniocalcin 1 is a Prognostic Biomarker in Glioma

Biom-16. A Targeted Gene Expression Biomarker Predicts Low Grade Meningioma Recurrence And Overall Survival

Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma

Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML)

A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence

Overexpression of Stathminï¿½1 Correlates with Poor Prognosis and Promotes Cell Migration and Proliferation in Oesophageal Squamous Cell Carcinoma

Stathmin 1 Expression Predicts Prognosis and Benefits from Adjuvant Chemotherapy in Patients with Gallbladder Carcinoma.

Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk

Holistic and network analysis of meningioma pathogenesis and malignancy.

Malignant Progression Contributes to the Failure of Combination Therapy for Atypical Meningiomas

A Microrna Expression Signature Predicts Meningioma Recurrence

Clinicopathologic Features and Prognostic Analysis of Atypical Meningiomas

MRI features and tumor-infiltrating CD8 + T cells-based nomogram for predicting meningioma recurrence risk

Clinical and Prognostic Features of Spinal Meningioma: a Thorough Analysis from a Single Neurosurgical Center.